Still in the renal denervation space? Startups, consider adaptive trial design, CRO says
After Medtronic‘s (MDT) January announcement it’s halting renal denervation trials and BSX and Covidien following suit, the medical blogosphere erupted, proclaiming the “fall” of renal denervation. It seems to be more than a little premature, considering there are other forms of renal denervation than RF (such as ReCor‘s ultrasound method) and other potential uses than for hypertension. […]